Fixed-Dose Combination Tablet with Segmented Release Layers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions for treating Type 2 diabetes with DPP-4 inhibitors and metformin lack efficient extended release mechanisms that ensure chemical stability, uniformity, and rapid dissolution of the active ingredients, particularly when combined with SGLT-2 inhibitors.
Innovation Solution
A fixed-dose combination of a DPP-4 inhibitor (linagliptin) and/or an SGLT-2 inhibitor (Compound A) is formulated with metformin in an extended release form, using a core matrix formulation with poly(ethylene oxide) and hydroxypropyl methylcellulose, and coated with an immediate release layer to achieve stable and rapid drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a fixed-dose combination of DPP-4 inhibitor and metformin is formulated, then uniform content and chemical stability are improved, but manufacturing complexity increases
Solution Approach 1:
The tablet is divided into two distinct layers: an extended-release core layer containing metformin and an immediate-release coating layer containing the DPP-4 inhibitor. This segmentation allows each layer to be optimized independently for its specific release profile, ensuring uniform content distribution and chemical stability while simplifying the manufacturing process through separate formulation and coating steps
Solution Approach 2:
The immediate-release coating layer is applied as a nested structure around the extended-release core layer. This nested design integrates two different release mechanisms into a single tablet unit, achieving uniform content delivery and chemical stability without requiring complex multi-step manufacturing processes
2Duration of action of moving object
If extended release mechanism is used for metformin, then duration of action is improved, but dissolution speed deteriorates
Solution Approach 1:
The tablet is segmented into two functional layers: the extended-release core layer provides sustained drug delivery over prolonged duration, while the immediate-release coating layer ensures rapid dissolution and quick onset of action. This segmentation resolves the contradiction by assigning different dissolution characteristics to different portions of the same dosage form
Solution Approach 2:
Different regions of the tablet are given different release properties: the core layer is formulated with extended-release matrix materials to provide slow, sustained release, while the outer coating layer is designed for immediate release. This local differentiation of quality allows the tablet to simultaneously achieve both fast initial dissolution and prolonged duration of action
3Speed
If immediate release coating is applied, then dissolution speed is improved, but manufacturing precision requirements increase
Solution Approach 1:
The extended-release core layer is prepared first with well-defined physical and chemical properties before the immediate-release coating is applied. This preliminary preparation establishes a stable base that facilitates uniform coating application, reducing the precision requirements for the subsequent coating step while ensuring rapid dissolution performance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides enhanced chemical stability, uniform content, low defect rates, and fast dissolution of the active ingredients, maintaining the extended release profile of metformin while ensuring immediate release of the DPP-4 or SGLT-2 inhibitor, suitable for a wide range of drug substance ratios and dosages.
Implementation Method 1
a core matrix formulation with poly(ethylene oxide) and hydroxypropyl methylcellulose
Implementation Method 2
extended release profile of metformin
Implementation Method 3
fast dissolution of the active ingredients, maintaining the extended release profile of metformin while ensuring immediate release of the DPP-4 or SGLT-2 inhibitor
Data Source
AI summary
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.